日本先天性巨细胞病毒流行病学及经济负担回顾性分析。

IF 2.2 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Philip O Buck, Debbie Goldschmidt, Annika Anderson, Noam Kirson, Urvi Desai, John Diaz-Decaro
{"title":"日本先天性巨细胞病毒流行病学及经济负担回顾性分析。","authors":"Philip O Buck, Debbie Goldschmidt, Annika Anderson, Noam Kirson, Urvi Desai, John Diaz-Decaro","doi":"10.1080/03007995.2025.2554734","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Congenital cytomegalovirus (cCMV) is a leading infectious cause of birth defects; approximately 20%-25% of infants with cCMV develop long-term health complications including hearing loss, microcephaly, and developmental issues. This study assessed the epidemiology and burden of clinically diagnosed cCMV in Japan.</p><p><strong>Methods: </strong>Insurance claims from the Japan Medical Data Center database (2011-2020) were analyzed retrospectively. Infants were included in the cCMV cohort if their first diagnosis (index date) of cCMV or CMV was within the birth/following month and had ≥24 months of continuous health plan enrollment post-index (study period). They were matched 1:1 to non-cCMV controls on sex, birth year, and index year. Birth prevalence was calculated annually through 2019. Healthcare resource utilization (HRU) and costs in 2023 Japanese Yen were summarized for the study period.</p><p><strong>Results: </strong>Birth prevalence of diagnosed cCMV during 2011-2019 ranged from 6.88-22.56 per 100,000 births. 121 matched pairs were included in the burden analysis. The mean number of medical encounters was significantly greater for infants with cCMV than controls in year one post-index (14.6 vs. 11.3, <i>p</i> < 0.0001), driven by outpatient encounters. Infants with cCMV were more likely than controls to have an inpatient admission in the first two years of life. Mean medical costs were significantly greater for infants with cCMV than controls in year one (¥1.6 M vs. ¥378K) and year two (¥483K vs. ¥194K).</p><p><strong>Conclusions: </strong>Infants diagnosed with cCMV in Japan had, on average, substantially higher HRU and healthcare cost burden than non-cCMV controls in the first two years of life.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-11"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retrospective claims analysis of the epidemiology and economic burden of diagnosed congenital cytomegalovirus in Japan.\",\"authors\":\"Philip O Buck, Debbie Goldschmidt, Annika Anderson, Noam Kirson, Urvi Desai, John Diaz-Decaro\",\"doi\":\"10.1080/03007995.2025.2554734\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Congenital cytomegalovirus (cCMV) is a leading infectious cause of birth defects; approximately 20%-25% of infants with cCMV develop long-term health complications including hearing loss, microcephaly, and developmental issues. This study assessed the epidemiology and burden of clinically diagnosed cCMV in Japan.</p><p><strong>Methods: </strong>Insurance claims from the Japan Medical Data Center database (2011-2020) were analyzed retrospectively. Infants were included in the cCMV cohort if their first diagnosis (index date) of cCMV or CMV was within the birth/following month and had ≥24 months of continuous health plan enrollment post-index (study period). They were matched 1:1 to non-cCMV controls on sex, birth year, and index year. Birth prevalence was calculated annually through 2019. Healthcare resource utilization (HRU) and costs in 2023 Japanese Yen were summarized for the study period.</p><p><strong>Results: </strong>Birth prevalence of diagnosed cCMV during 2011-2019 ranged from 6.88-22.56 per 100,000 births. 121 matched pairs were included in the burden analysis. The mean number of medical encounters was significantly greater for infants with cCMV than controls in year one post-index (14.6 vs. 11.3, <i>p</i> < 0.0001), driven by outpatient encounters. Infants with cCMV were more likely than controls to have an inpatient admission in the first two years of life. Mean medical costs were significantly greater for infants with cCMV than controls in year one (¥1.6 M vs. ¥378K) and year two (¥483K vs. ¥194K).</p><p><strong>Conclusions: </strong>Infants diagnosed with cCMV in Japan had, on average, substantially higher HRU and healthcare cost burden than non-cCMV controls in the first two years of life.</p>\",\"PeriodicalId\":10814,\"journal\":{\"name\":\"Current Medical Research and Opinion\",\"volume\":\" \",\"pages\":\"1-11\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Medical Research and Opinion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/03007995.2025.2554734\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Research and Opinion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/03007995.2025.2554734","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

目的:先天性巨细胞病毒(cCMV)是导致出生缺陷的主要传染病;大约20%-25%患有cCMV的婴儿会出现长期健康并发症,包括听力损失、小头畸形和发育问题。本研究评估了日本临床诊断的cCMV的流行病学和负担。方法:回顾性分析日本医疗数据中心数据库2011-2020年保险理赔数据。如果首次诊断为cCMV或CMV(指数日期)的婴儿在出生/出生后一个月内,并且在指数(研究期)后连续参加健康计划≥24个月,则将其纳入cCMV队列。在性别、出生年份和索引年份方面,他们与非ccmv对照组的比例为1:1。出生患病率每年计算一次,直到2019年。总结了研究期间2023年日元医疗资源利用率(HRU)和成本。结果:2011-2019年,cCMV的出生患病率为6.88-22.56 / 10万。121对配对的夫妇被纳入负担分析。结论:在日本,诊断为cCMV的婴儿在出生后两年的平均HRU和医疗费用负担明显高于非cCMV对照组。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Retrospective claims analysis of the epidemiology and economic burden of diagnosed congenital cytomegalovirus in Japan.

Objective: Congenital cytomegalovirus (cCMV) is a leading infectious cause of birth defects; approximately 20%-25% of infants with cCMV develop long-term health complications including hearing loss, microcephaly, and developmental issues. This study assessed the epidemiology and burden of clinically diagnosed cCMV in Japan.

Methods: Insurance claims from the Japan Medical Data Center database (2011-2020) were analyzed retrospectively. Infants were included in the cCMV cohort if their first diagnosis (index date) of cCMV or CMV was within the birth/following month and had ≥24 months of continuous health plan enrollment post-index (study period). They were matched 1:1 to non-cCMV controls on sex, birth year, and index year. Birth prevalence was calculated annually through 2019. Healthcare resource utilization (HRU) and costs in 2023 Japanese Yen were summarized for the study period.

Results: Birth prevalence of diagnosed cCMV during 2011-2019 ranged from 6.88-22.56 per 100,000 births. 121 matched pairs were included in the burden analysis. The mean number of medical encounters was significantly greater for infants with cCMV than controls in year one post-index (14.6 vs. 11.3, p < 0.0001), driven by outpatient encounters. Infants with cCMV were more likely than controls to have an inpatient admission in the first two years of life. Mean medical costs were significantly greater for infants with cCMV than controls in year one (¥1.6 M vs. ¥378K) and year two (¥483K vs. ¥194K).

Conclusions: Infants diagnosed with cCMV in Japan had, on average, substantially higher HRU and healthcare cost burden than non-cCMV controls in the first two years of life.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Medical Research and Opinion
Current Medical Research and Opinion 医学-医学:内科
CiteScore
4.40
自引率
4.30%
发文量
247
审稿时长
3-8 weeks
期刊介绍: Current Medical Research and Opinion is a MEDLINE-indexed, peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, Phase II-IV studies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged. Preclinical, Phase I, pharmacoeconomic, outcomes and quality of life studies may also be considered if there is clear clinical relevance
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信